MGD-22

MGD-22 is a potent triple degrader of IKZF1, IKZF2, and IKZF3, featuring a phthalazinone scaffold. It operates through the Cullin-CRBN pathway, inducing robust degradation of these targets. The drug has demonstrated nanomolar-range IC50 potencies across various hematological cancer cell lines, including multiple myeloma (MM), acute myeloid leukemia (AML), and diffuse large B-cell lymphoma (DLBCL), and has shown the ability to overcome acquired resistance to pomalidomide. Orally administered MGD-22 has exhibited significant tumor growth inhibition in preclinical models with favorable pharmacokinetic properties and synergistic effects when combined with Bruton's tyrosine kinase (BTK) and B-cell lymphoma-2 (BCL-2) inhibitors in DLBCL cancer cells. These findings position MGD-22 as a promising therapeutic candidate for hematological cancers.